Skip to main content
OpenTrials
Completed

NCT Number: NCT01807676

Prospective, Randomized Clinical Trial Evaluating the ETView Double-Lumen Tube

No prospective randomized clinical trial assessed the performance of this new device in a clinical setting. Consequently the aim of this study is to determine clinical performance of this new device compared with conventional DLT.

* Trial with medical device

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Hospital Zurich, Division of Anaesthesiology

Zurich, Canton of Zurich, 8091, Switzerland

About this study

In several clinical situations and surgical procedures single-lung ventilation (SLV) is essential. Especially during thoracic surgery SLV and collapse of the operated lung, while ventilating the other side of the lung is the most frequented indication. In these cases the double lumen tube (DLT) is the most widely used device.

The DLT consists of a proximal tracheal and a distal bronchial end, reaching into the left or the right side of the lung- dependent of the model of the tube. Endotracheal intubation with DLT, which are much larger and stiffer than conventional single-lumen tubes, are much more difficult to place and are especially likely to provoke airway injuries. Furthermore, placement of a DLT requires obligatory fiberoptic bronchoscopy and a certain level of experience. Tube misplacement after patients removal from dorsal (intubation-) to lateral position as well as during surgical procedure is relatively frequent. Tube displacement from its proper position above the carina, respectively in the main bronchus, may result in life-threating complications and airway lacerations.

The anesthetist may detect tube misplacement from indirect clinical signs including increased airway pressure, oxygen desaturation, or difficulty performing SLV. In this clinical situations, verification of tube position using fibreoptic bronchoscopy is indicated. Fibreoptic bronchoscopy requires rigorous training and practice to maintain a high level of skill as well as expensive infrastructure.

The VivaSight-DL (ETView Ltd, M.P. Misgav 20174, Israel) is a new DLT promising to exceed clinical performance of the conventional DLT. The VivaSight-DL is basically a left-sided DLT with an embedded video imaging device and light source at its tip and integrated cable with connector. However, after correct tube placement, the video imaging device is focused on the main carina, indicating the correct position of the bronchial cuff in the left main bronchus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elective thoracic surgery with anticipated use of a DLT
  • Anticipated extubation in the operating room;
  • American Society of Anesthesiologist Physical Status 1-3;
  • Age 18- 90.
  • Written consent (signature from patient)

Exclusion criteria

  • Tracheal pathology, including tracheostomy;
  • Any form of infection (including upper-respiratory tract infection or pneumonia) or suspected tuberculosis;
  • BMI higher exceeding 40 kg/m2;
  • Known or suspected difficult airway.
  • Pregnancy
  • Breast feeding
  • The subject must not be involved in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion

Treatment and study plan

ET View Double Lumen Tube

Device

Other names: VivaSight-DL (ETView Ltd, M.P. Misgav 20174, Israel)

Conventional Double Lumen Tube

Device

Other names: conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany)

Primary outcomes

  1. time to intubation

    Time frame: 300 seconds

    Time for intubation, defined as "time from insertion of the laryngoscope until statement of the intubating anesthesiologist, that DLT was correctly placed". Time for intubation will be measured by an independent researcher using a stop watch.

Secondary outcomes

  1. Rate of misplacement

    Time frame: 3 hours

    Rate of misplacement, occurring after patients removal from dorsal to lateral position

  2. Rate of misplacement

    Time frame: 3 hours

    Rate of misplacement, occurring during surgery, potentially caused by vibrations and movements by surgeons

  3. Rate of blind insertion

    Time frame: 300 seconds

    Rate of blind insertion, defined as successful placement of airway device in correct position in trachea/ main stream bronchus without help of fibreoptic bronchoscopy8

  4. rate of fibreoptic bronchoscopy

    Time frame: 3 hours

    Necessity of tube re-placement by fibreoptic bronchoscopy

  5. Quality of lung collapse

    Time frame: 3 hours

  6. Airway injuries

    Time frame: 3 hours

  7. Postoperative coughing

    Time frame: 24 hours

  8. Postoperative hoarseness

    Time frame: 24 hours

  9. Postoperative sore throat

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Mar 8, 2013
Registry last updated
Apr 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.